WO2003044018A1 - Amides d'acide 1h-pyrrolo[3,2-b]pyridine-3-carboxylique - Google Patents

Amides d'acide 1h-pyrrolo[3,2-b]pyridine-3-carboxylique Download PDF

Info

Publication number
WO2003044018A1
WO2003044018A1 PCT/US2002/037157 US0237157W WO03044018A1 WO 2003044018 A1 WO2003044018 A1 WO 2003044018A1 US 0237157 W US0237157 W US 0237157W WO 03044018 A1 WO03044018 A1 WO 03044018A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkoxy
pyrrolo
carboxylic acid
pyridine
Prior art date
Application number
PCT/US2002/037157
Other languages
English (en)
Inventor
George D. Maynard
Manuka Ghosh
Christopher J. O'donnell
Original Assignee
Neurogen Corporation
Pfizer Products, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corporation, Pfizer Products, Inc. filed Critical Neurogen Corporation
Priority to EP02803679A priority Critical patent/EP1453831A1/fr
Priority to MXPA04004711A priority patent/MXPA04004711A/es
Priority to JP2003545655A priority patent/JP2005516901A/ja
Priority to BR0214301-1A priority patent/BR0214301A/pt
Priority to CA002467542A priority patent/CA2467542A1/fr
Priority to AU2002366092A priority patent/AU2002366092A1/en
Publication of WO2003044018A1 publication Critical patent/WO2003044018A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des amides d'acide 1H-pyrrolo[3,2-b]pyridine-3-carboxylique qui se lient au site benzodiazépine de récepteurs GABAA. De tels composés peuvent être utilisés pour moduler la liaison de ligands à des récepteurs GABAA in vivo et in vitro et sont particulièrement utiles dans le traitement de divers troubles du système nerveux central chez l'homme, les animaux de compagnie domestiqués et le bétail.
PCT/US2002/037157 2001-11-19 2002-11-19 Amides d'acide 1h-pyrrolo[3,2-b]pyridine-3-carboxylique WO2003044018A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP02803679A EP1453831A1 (fr) 2001-11-19 2002-11-19 Amides d'acide 1h-pyrrolo(3,2-b)pyridine-3-carboxylique
MXPA04004711A MXPA04004711A (es) 2001-11-19 2002-11-19 Amidas del acido 1h-pirrolo(3,2-b(piridin-3-carboxilico.
JP2003545655A JP2005516901A (ja) 2001-11-19 2002-11-19 １Ｈ−ピロロ［３，２−ｂ］ピリジン−３−カルボン酸アミド化合物
BR0214301-1A BR0214301A (pt) 2001-11-19 2002-11-19 Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratar doenças ou condições, para potencializar um efeito terapêutico de um agente do snc, para melhorar a memória recente de um paciente, para determinar a presença ou ausência de um receptor de gabaa em uma amostra, e para alterar a atividade de transdução de sinal de receptor de gabaa, preparação farmacêutica acondicionada, e, uso de um composto ou sal
CA002467542A CA2467542A1 (fr) 2001-11-19 2002-11-19 Amides d'acide 1h-pyrrolo[3,2-b]pyridine-3-carboxylique
AU2002366092A AU2002366092A1 (en) 2001-11-19 2002-11-19 1h-pyrrolo(3,2-b)pyridine-3-carboxylic acid amides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33302701P 2001-11-19 2001-11-19
US60/333,027 2001-11-19

Publications (1)

Publication Number Publication Date
WO2003044018A1 true WO2003044018A1 (fr) 2003-05-30

Family

ID=23300941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/037157 WO2003044018A1 (fr) 2001-11-19 2002-11-19 Amides d'acide 1h-pyrrolo[3,2-b]pyridine-3-carboxylique

Country Status (7)

Country Link
EP (1) EP1453831A1 (fr)
JP (1) JP2005516901A (fr)
AU (1) AU2002366092A1 (fr)
BR (1) BR0214301A (fr)
CA (1) CA2467542A1 (fr)
MX (1) MXPA04004711A (fr)
WO (1) WO2003044018A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865208A1 (fr) * 2004-01-16 2005-07-22 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
WO2007026104A1 (fr) * 2005-09-01 2007-03-08 Laboratoires Fournier S.A. Derives de pyrrolopyridine et leurs utilisations comme modulateurs des recepteurs ppar
WO2013120438A1 (fr) 2012-02-14 2013-08-22 中国科学院上海生命科学研究院 Substance pour le traitement ou le soulagement de la douleur
US9926312B2 (en) 2013-10-01 2018-03-27 Eisai R&D Management Co., Ltd. 4-azaindole derivatives
US10562912B2 (en) 2013-06-05 2020-02-18 C&C Research Laboratories Heterocyclic derivatives and use thereof
WO2023082044A1 (fr) * 2021-11-09 2023-05-19 暨南大学 Composé amide hétérocyclique de 5-formyle et son utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002420A1 (fr) * 1996-07-16 1998-01-22 Neurogen Corporation Certains pyrrolecarboxanilides condenses, une nouvelle classe de ligands du recepteur gaba

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002420A1 (fr) * 1996-07-16 1998-01-22 Neurogen Corporation Certains pyrrolecarboxanilides condenses, une nouvelle classe de ligands du recepteur gaba

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589201B2 (en) 2004-01-16 2009-09-15 Sanofi-Aventis Derivatives of 1,4-diazabicyclo[3.2.1]octanecarboxamide, preparation method thereof and use of same in therapeutics
WO2005077955A1 (fr) * 2004-01-16 2005-08-25 Sanofi-Aventis Derives de 1,4-diazabicyclo[3.2.1]octanecarboxamide, leur preparation et leur application en therapeutique
FR2865208A1 (fr) * 2004-01-16 2005-07-22 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
EA014185B1 (ru) * 2005-09-01 2010-10-29 Лабораториз Фурнье С.А. Производные пирролопиридина и их применение в качестве модуляторов ppar-рецепторов
US7557122B2 (en) 2005-09-01 2009-07-07 Laboratoires Fournier S.A. Pyrrolopyridine compounds, method of making them and uses thereof
US7728002B2 (en) 2005-09-01 2010-06-01 Laboratoires Fournier S.A. Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors
WO2007026104A1 (fr) * 2005-09-01 2007-03-08 Laboratoires Fournier S.A. Derives de pyrrolopyridine et leurs utilisations comme modulateurs des recepteurs ppar
CN101242833B (zh) * 2005-09-01 2012-06-27 实验室富尼耶公司 吡咯并吡啶衍生物及其作为ppar受体调控剂的用途
NO340681B1 (no) * 2005-09-01 2017-05-29 Inventiva Pyrrolopyridinderivater, framgangsmåte for fremstilling, farmasøytisk praparater omfattende slike, slike forbindelser som farmakologisk aktive substanser samt anvendelse av slike forbindelser og preparater for behandling av sykdom
WO2013120438A1 (fr) 2012-02-14 2013-08-22 中国科学院上海生命科学研究院 Substance pour le traitement ou le soulagement de la douleur
US10562912B2 (en) 2013-06-05 2020-02-18 C&C Research Laboratories Heterocyclic derivatives and use thereof
US9926312B2 (en) 2013-10-01 2018-03-27 Eisai R&D Management Co., Ltd. 4-azaindole derivatives
US10072005B2 (en) 2013-10-01 2018-09-11 Eisai R&D Management Co., Ltd. 4-azaindole derivatives
WO2023082044A1 (fr) * 2021-11-09 2023-05-19 暨南大学 Composé amide hétérocyclique de 5-formyle et son utilisation

Also Published As

Publication number Publication date
MXPA04004711A (es) 2005-08-16
BR0214301A (pt) 2004-10-13
JP2005516901A (ja) 2005-06-09
EP1453831A1 (fr) 2004-09-08
CA2467542A1 (fr) 2003-05-30
AU2002366092A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
US6653471B2 (en) Heterocyclic compounds as ligands of the GABAA receptor
US6552037B2 (en) 2-Substituted imidazo[1,2-A]pyridine derivatives
EP1177177B1 (fr) 4-oxo-quinoline-3-carboxamides substitues: ligands des recepteurs cerebraux gaba
US6828329B2 (en) Aryl fused substituted 4-oxy-pyridines
EP1406906A1 (fr) Composes heteroaryles bicycliques fondus a substitution heteroaryle utilises comme ligands des recepteurs gabaa
US6656941B2 (en) Aryl substituted tetrahydroindazoles
AU7092800A (en) Fused pyrrolecarboxamides: gaba brain receptor ligands
WO2003044018A1 (fr) Amides d'acide 1h-pyrrolo[3,2-b]pyridine-3-carboxylique
US6673811B1 (en) 1H-pyrrolo [3,2-b] pyridine-3-carboxylic acid amines as GABAA receptor ligands
US6743817B2 (en) Substituted fused pyrroleimines and pyrazoleimines
EP1499608A1 (fr) Derives d'imidazole substitues: ligands du recepteur gaba a
EP1506194B1 (fr) Derives d'imidazole a cycles fusionnes se fixant aux recepteurs gaba sb a /sb , ligands des recepteurs gaba sb a /sb
AU2002320465A1 (en) Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2467542

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/004711

Country of ref document: MX

Ref document number: 2003545655

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002803679

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002803679

Country of ref document: EP